Welcome to our teaching unit on treatment and prevention of Ebola virus disease. Learning objectives are: to consider relevant treatment strategies for Ebola virus disease, to highlight the current state of development of specific anti-Ebola medications and their general working mechanisms, to discuss preventative strategies and the logic behind them, and to look into the current state of development of long-term preventative approaches for example vaccines. With regard to treatment, the mainstay of therapy up-to-date is supportive care. However, in the future, improved supportive care specific anti-Ebola viral drugs and monoclonal antibodies will come into the picture and this will be discussed in this module. With regard to prevention, personal protection is of paramount importance of course, and in the future we hope that we will have vaccines at hand. Generally, the current supportive care is the only established way of supporting our patients in order to recover from Ebola virus disease. We will discuss the various supportive care strategies, most important is certainly re-hydration. Most important is replenishment of electrolytes, et cetera and then we will look into the various other supportive means of care. Experimental treatment approaches are consisting of the use of blood products from reconvalescents. This is nothing really new. This has been experimented with on a much smaller scale naturally during smaller outbreaks in the past already. This approach is now revitalized and studied most thoroughly. Then of course the development of specific anti-Ebola drugs and antibodies will be discussed. What experimental drugs are there? Well, there are a couple of anti-retrovirals with specific effect or a particular good effect, virocidal effect on Ebola virus, for example, Favipiravir comes into the picture here that we'll be discussed in detail and then there are a couple of other drugs and monoclonal antibodies, which we will discuss in detail, which are under development. Mind you, this is an extremely rapidly evolving field at present and all our information is up-to-date at the moment of producing the course, but that may in some details very quickly be outdated and superseded by more data becoming available. Prospects for vaccination development, for vaccine development actually, there are a couple of vaccines which have been fast-tracked now from an macaque animal study stage actually into humans. There are a couple of phase one trials on their way, not only in Africa, but also in certain European settings. Several of them are already reaching completion in their first stages and we expect first, phase one study results to become available very very quickly, either still before the course goes online or within the next two or three couple of months actually. Prevention, personal protection, of course is paramount here. We discuss mainly treatment, but we also want to lay the link gain to prevention, personal protection. However, we are going to discuss this of course in much more detail in some of the practical learning and experience sharing units actually. Our conclusion will be that the current treatment approach is mainly supportive actually. We will- that there are a couple of experimental treatments in development, that personal protection is paramount and that the vaccine development has now reached critical speed and at least before this outbreak, the current outbreak, will come to an end or ease off, there will be phase one data at least available for a range of potential vaccines actually. As well and as always, our learning unit will be supplemented by ample reading material. Thank you very much for your attention.